DK1632248T3 - Anti-interleukin-9-antistof eller anti-interleukin-9-receptor-antistof til behandling af bronkial overfølsomhed - Google Patents

Anti-interleukin-9-antistof eller anti-interleukin-9-receptor-antistof til behandling af bronkial overfølsomhed

Info

Publication number
DK1632248T3
DK1632248T3 DK05009688.2T DK05009688T DK1632248T3 DK 1632248 T3 DK1632248 T3 DK 1632248T3 DK 05009688 T DK05009688 T DK 05009688T DK 1632248 T3 DK1632248 T3 DK 1632248T3
Authority
DK
Denmark
Prior art keywords
interleukin
antibody
treatment
receptor
bronchial hypersensitivity
Prior art date
Application number
DK05009688.2T
Other languages
Danish (da)
English (en)
Inventor
W Lee Maloy
Prasad U Kari
Nicholas Nicolaides
Original Assignee
Ligand Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ligand Pharm Inc filed Critical Ligand Pharm Inc
Application granted granted Critical
Publication of DK1632248T3 publication Critical patent/DK1632248T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5425—IL-9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
DK05009688.2T 1995-08-24 1996-08-23 Anti-interleukin-9-antistof eller anti-interleukin-9-receptor-antistof til behandling af bronkial overfølsomhed DK1632248T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US276595P 1995-08-24 1995-08-24
US2380096P 1996-08-06 1996-08-06
EP96929657A EP0846173B1 (en) 1995-08-24 1996-08-23 Use of an anti-interleukin-9 antibody for the preparation of a medicament for the treatment of asthma

Publications (1)

Publication Number Publication Date
DK1632248T3 true DK1632248T3 (da) 2011-01-24

Family

ID=26670837

Family Applications (2)

Application Number Title Priority Date Filing Date
DK96929657T DK0846173T3 (da) 1995-08-24 1996-08-23 Anvendelse af et anti-interleukin-9-antistof til fremstilling af et lægemiddel til behandling af astma
DK05009688.2T DK1632248T3 (da) 1995-08-24 1996-08-23 Anti-interleukin-9-antistof eller anti-interleukin-9-receptor-antistof til behandling af bronkial overfølsomhed

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK96929657T DK0846173T3 (da) 1995-08-24 1996-08-23 Anvendelse af et anti-interleukin-9-antistof til fremstilling af et lægemiddel til behandling af astma

Country Status (10)

Country Link
EP (3) EP0846173B1 (enExample)
JP (3) JP3948495B2 (enExample)
AT (2) ATE484294T1 (enExample)
AU (1) AU6895696A (enExample)
CA (2) CA2666298A1 (enExample)
DE (2) DE69638281D1 (enExample)
DK (2) DK0846173T3 (enExample)
ES (2) ES2249786T3 (enExample)
PT (1) PT1632248E (enExample)
WO (1) WO1997008321A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830454A (en) * 1996-08-30 1998-11-03 Ludwig Institute For Cancer Research Method for treating cell mediated autoimmune disorders using interleukin-9
AU746595B2 (en) * 1996-12-02 2002-05-02 Genaera Corporation IL-9 receptor variants, useful in treating and diagnosing atopic allergies including asthma and related disorders
EP1471144B1 (en) * 1996-12-02 2010-06-23 Genaera Corporation Biological variability of asthma associated factor AAF2 (IL-9 receptor) useful in treating and diagnosing atopic allergies including asthma and related disorders
AU5532098A (en) * 1996-12-20 1998-07-17 Magainin Pharmaceuticals, Inc. A method for diagnosis and treatment of inflammatory bowel diseases including crohn's disease and chronic ulcerative colitis
JP2001517682A (ja) * 1997-09-19 2001-10-09 マガイニン ファーマシューティカルズ インク． 喘息および関連疾患を含むアトピー性アレルギーを治療するための標的としての喘息関連因子
EP1015492A2 (en) * 1997-09-19 2000-07-05 Magainin Pharmaceuticals Inc. Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
AU781995B2 (en) * 1999-05-01 2005-06-23 Genaera Corporation Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
WO2002100432A1 (en) * 2001-06-08 2002-12-19 Genaera Corporation Methods for the modulation of il-13
WO2001059142A1 (en) * 2000-02-09 2001-08-16 Medimmune, Inc. Antibody gene therapy with adeno-associated viral vectors
AU2002303098A1 (en) * 2001-02-22 2002-09-12 The Research Foundation Of State University Of New York Opiate receptors
WO2004091519A2 (en) * 2003-04-11 2004-10-28 Medimmune, Inc. Methods of preventing or treating respiratory conditions
US7470521B2 (en) 2004-07-20 2008-12-30 Critical Therapeutics, Inc. RAGE protein derivatives
US7635754B2 (en) * 2004-09-22 2009-12-22 Aerovance, Inc. Interleukin-9 and interleukin-4 chimeric antagonist muteins and methods of using same
US8354106B2 (en) 2005-06-16 2013-01-15 The Feinstein Institute For Medical Research Antibodies against HMGB1 and fragments thereof
WO2008039941A2 (en) 2006-09-27 2008-04-03 The Government Of The Usa As Represented By The Secretary Of The Dpt. Of Health And Human Services Scgb3a2 as a growth factor and anti-apoptotic agent
JP5564167B2 (ja) * 2008-05-22 2014-07-30 日本たばこ産業株式会社 苦味マスキング剤及び苦味低減方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208218A (en) * 1988-09-19 1993-05-04 Ludwig Institute For Cancer Research T cell growth factor glycoproteins
US5414071A (en) 1989-05-23 1995-05-09 Genetics Institute, Inc. Human cytokine IL-9
US5132109A (en) * 1990-10-05 1992-07-21 Ludwig Institute For Cancer Research Method for inhibiting production of ige and method for enhancing production of igg using interleukin 9 and inhibitors thereof
JPH09511400A (ja) 1994-03-30 1997-11-18 ユニバーシティ オブ メリーランド アット ボルティモア 交互スプライシングによって生成されるヒトインターロイキン変異体

Also Published As

Publication number Publication date
DK0846173T3 (da) 2006-01-16
EP0846173B1 (en) 2005-10-19
ATE307203T1 (de) 2005-11-15
ES2354360T3 (es) 2011-03-14
JPH11514851A (ja) 1999-12-21
DE69635305T2 (de) 2006-07-06
CA2230240C (en) 2009-08-18
CA2230240A1 (en) 1997-03-06
DE69635305D1 (de) 2006-03-02
EP1632248A1 (en) 2006-03-08
EP2241329A3 (en) 2011-03-09
ES2249786T3 (es) 2006-04-01
DE69638281D1 (de) 2010-11-25
JP3948495B2 (ja) 2007-07-25
ATE484294T1 (de) 2010-10-15
WO1997008321A1 (en) 1997-03-06
EP1632248B8 (en) 2010-12-29
PT1632248E (pt) 2010-12-28
JP4813380B2 (ja) 2011-11-09
EP2241329A2 (en) 2010-10-20
JP2011152135A (ja) 2011-08-11
AU6895696A (en) 1997-03-19
EP1632248B1 (en) 2010-10-13
CA2666298A1 (en) 1997-03-06
EP0846173A1 (en) 1998-06-10
JP2007169287A (ja) 2007-07-05

Similar Documents

Publication Publication Date Title
DK1632248T3 (da) Anti-interleukin-9-antistof eller anti-interleukin-9-receptor-antistof til behandling af bronkial overfølsomhed
HUP9700603A1 (hu) Gyógyászati készítmény véralvadási zavarok kezelésére
DK1382348T3 (da) Polynukleotidvaccineformulering, især til behandling af bovin luftvejssygdom
DK0941103T3 (da) Farmaceutisk præparat til behandling af diabetes
ATE271393T1 (de) Zusammensetzungen zur erhöhung des hautdurchtritts von arzneistoffen unter verwendung von permeationsbeschleunigern
UA27911C2 (uk) Засіб для лікування або запобігання фізіологічних розладів, які викликані надлишком тахікініну
ATE133564T1 (de) Flupirtin in kombination mit antiparkinsonika zur bekämpfung von muskelverspannungen
DK0751129T3 (da) Substituerede dihydrodibenz/b,f/azepiner, fremgangsmåde til fremstilling deraf, deres anvendelse i behandlingen af nogle li
CY2610B2 (en) Prevention and treatment of skeletal disorder with EP2 receptor subtype selective prostaglandin E2 a gonists
FI961083L (fi) Rekombinentti-IL4-vasta-aineita, jotka ovat käyttökelpoisia IL-4-välitteisten häiriötilojen hoidossa
NO992674L (no) Konturen til et transdermalt terapeutisk system
FR2684289B1 (fr) Implant intra-cortical, notamment pour la fixation de ligament.
FR2684543B1 (fr) Ligament artificiel, notamment pour la cheville.
ES2195000T3 (es) Composicion farmaceutica.
DK671087D0 (da) Anvendelse af 5-aryl-3h-1,2,4-triazol-3-oner som antikonvulsiva
DE69734461D1 (de) Verwendung von mycobacterium vaccae zur therapie des chronischen müdigkeitssyndrom
BR0208554A (pt) Osteoprotegerina no leite
TR26959A (tr) Kemiklerin tesbitine mahsus yardimci osteosentez vasitasi.
EP0566140A3 (en) Process for the preparation of polyphosphate dinucleoside, polyphosphate nucleoside or their derivatives.
DK0956038T3 (da) Morfogen peptidinduceret regeneration af senseopfattelsesvæv
ES1004869Y (es) Atadura para la fijacion de sarmientos.
DK475989D0 (da) Anvendelse af pyrazolopyridinderivater eller fysiologisk acceptable salte deraf i laegmidler til behandling af epilepsi
DE68918449D1 (de) Siliziumverbindungen zur behandlung von knochen.
ES1013923Y (es) Atadura para la fijacion de sarmientos.
DE69002821D1 (de) Zusammensetzung zur haarbehandlung.